Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy.

Miura, Itaru; Horikoshi, Sho; Ichinose, Mizue; Suzuki, Yuhei; Watanabe, Kenya

Miura, Itaru; Horikoshi, Sho; Ichinose, Mizue; Suzuki, Yuhei; Watanabe, Kenya.

Afiliação

Miura I; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Horikoshi S; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Ichinose M; Department of Neuropsychiatry, Horikoshi Psychosomatic Clinic, Fukushima, Japan.
Suzuki Y; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Watanabe K; Department of Neuropsychiatry, Hoshigaoka Hospital, Koriyama, Japan.

Drug Des Devel Ther ; 17: 3023-3031, 2023.

Article em En | MEDLINE | ID: mdl-37789971

Assuntos

Antipsicóticos; Esquizofrenia; Humanos; Cloridrato de Lurasidona/efeitos adversos; Esquizofrenia/tratamento farmacológico; Serotonina; Isoindóis/farmacologia; Tiazóis/farmacologia; Antipsicóticos/efeitos adversos; Aumento de Peso

Palavras-chave

antipsychotics; lurasidone; schizophrenia; serotonin-dopamine antagonist

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google